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Background and Purpose: Glioblastomas are the most aggressive of all gliomas. The
prognosis of these gliomas, which are classified as grade IV tumors by the World Health
Organization (WHO), is poor. Combination therapy, including surgery, radiotherapy, and
chemotherapy has variable outcomes and is expensive. In light of rising healthcare
costs, there are societal demands for the justification of medical expenses. Therefore,
we calculated the cost-effectiveness of follow-up [18F] fluoroethyl-L-tyrosine ([18F] FET)
positron emission tomography (PET) scans performed on patients with glioblastoma after
surgery and before commencing temozolomide maintenance treatment.
Materials and Methods: To determine the cost-effectiveness of follow-up [18F] FET
PET procedures, we examined published clinical data and calculated the associated
costs in the context of Belgian healthcare. We subsequently performed one-way
deterministic sensitivity analysis and Monte Carlo analysis on the calculated ratios.
Results: The decision tree based on overall survival rates showed that the
number of non-responders identified using PET was 57.14% higher than the number
of non-responders identified using conventional MRI. Further, the decision tree
based on progression-free survival rates revealed a comparable increase of 57.50%
non-responders identified. The calculated cost of two required PET scans per patient
during the follow-up treatment phase was 780.50 euros. Two cost-effectiveness ratios
were determined for overall survival and progression-free survival rates. Both of these
calculations yielded very similar results: incremental cost-effectiveness ratios of 1,365.86
and 1,357.38 euros, respectively, for each identified non-responder. The findings of the
sensitivity analysis supported the calculated results, confirming that the obtained data
were robust.
Conclusion: Our comparative study of conventional MRI and [18F] FET PET revealed
that the latter is a valuable tool for predicting the treatment responses of patients with
glioblastomas to follow-up temozolomide maintenance treatment while considering its
cost-effectiveness. Thus, [18F] FET PET scans enable clinical outcomes to be predicted
accurately and at a low cost. Moreover, given the robustness of the data in the sensitivity
analyses, the level of certainty of this outcome is acceptable.
Keywords: [18F] fluoroethyl-L-tyrosine, cost-effectiveness, positron emission tomography, glioblastoma,
temozolomide
Baguet et al. Cost-Effectiveness of [18F] FET
INTRODUCTION
Glioblastomas account for 54% of all gliomas in adults and are
considered the most aggressive tumors within this category (1).
Categorized by the World Health Organization (WHO) as grade
IV gliomas, they either develop from a low-grade glioma or
originate de novo. Symptoms are usually severe and are caused by
space-occupying lesions. The state-of-the-art treatment consists
of surgery followed by adjuvant combination therapy that entails
radiochemotherapy and six cycles of maintenance chemotherapy
using temozolomide (TMZ) (2, 3). However, the prognosis
remains poor, with only one-third of patients surviving for more
than 2 years after diagnosis (4, 5).
In clinical practice, symptomatic patients with a suspected
brain tumor undergo magnetic resonance imaging (MRI) of the
brain. MRI is the imaging technique of choice for diagnosis
because of its excellent soft tissue contrast (6, 7). However, there
are shortcomings associated with this technique. In particular,
during the follow-up phase, it is difficult to discriminate between
pseudo-progression after the completion of treatment vs. tumor
progression using conventional MRI. This is because contrast
enhancement with MRI is an aspecific finding that merely
indicates leakage of the contrast medium through the blood-
brain-barrier, which may be treatment related (8, 9).
Advanced MR imaging modalities, such as diffusion- and
perfusion-weighted MRI and MR spectroscopy, are potentially
able to differentiate between pseudo- and real progression more
effectively than anatomical MRI used on its own can. Moreover,
positron emission tomography (PET) imaging may enable this
differentiation, as it allows for the visualization of specific
biological processes. For brain tumor imaging conducted with
PET, amino acid analogs are preferred as PET tracers. This is
because they do not show significant uptake in inflammatory
tissue and are therefore less influenced by phenomena such as
pseudoprogression and pseudoresponse (8, 9).
It is also noteworthy that after the treatment is completed,
biological changes usually precede anatomical alterations.
Therefore, PET imaging can potentially enable early detection of
therapy responses (10, 11).
This role of PET imaging was further explored by Galldiks
et al. (12), who compared the capability of [18F]-fluoroethyl-L-
tyrosine ([18F] FET) PET for assessing therapy responses after
administering TMZ and radiotherapy with that of MRI. The
authors correlated changes in [18F] FET uptake with changes in
contrast-enhancing tumor volume shown in T1-weighed MRI
images after surgery and treatment with TMZ. They concluded
that [18F] FET PET could be a valuable tool for predicting
the therapy outcome prior to the commencement of TMZ
maintenance therapy. This is an important finding given the
potentially severe side-effects of TMZ. Hence, the authors argued
Abbreviations: [18F] FET, [18F] Fluoroethyl-L-tyrosine; [18F] FDOPA,
[18F] fluorodihydroxyphenylalanine; ICER, Incremental cost-effectiveness
ratio; MRI, Magnetic Resonance Imaging; N, Chance node; PET, Positron
Emission Tomography; TBR, Tumor-to-background; TBRmax, maximal
tumor-to-background; TMZ, Temozolomide; WHO, World Health Organization.
that therapy should be tailored to each specific patient based on
the results of the acquired [18F] FET PET image.
However, incorporating [18F] FET PET into daily clinical
routines is associated with increased medical costs and can only
be justified when there are sufficient benefits associated with its
use in terms of improved survival rates as well as quality of life.
Therefore, our aim was to perform an economic analysis of [18F]
FET PET imaging in patients with glioblastoma during follow-
up treatment. The economic analysis was done on a sample of
glioblastoma patients to obtain a homogeneous group, receiving
the same treatment. For every patient, therapy consisted of
surgery followed by adjuvant radiotherapy and concomitant
temozolomide. Upon completion of radiochemotherapy the
patient received maintenance temozolomide. To the best of our
knowledge, a comparison of the cost-effectiveness of [18F] FET
PET and MRI for predicting therapy responses has not been
undertaken to date.
MATERIALS AND METHODS
Input Data
The effectiveness of identifying responders and non-responders
with PET and MRI was determined using clinical data obtained
from Galldiks et al. (12). Twenty-five patients diagnosed with
glioblastoma, who underwent resection (13 partial resections
and 12 gross total resections), were included in their study.
Both PET and MRI scans were performed 11–20 days post-
surgery (MRI-1, FET-1). Following neurosurgery, the patients
underwent adjuvant combined radiotherapy and TMZ treatment.
Within 7–10 days after radiochemotherapy commenced, PET
and MRI scans were repeated (MRI-2, FET-2). Following
a 4-weeks break, the patients underwent another six cycles
of TMZ. A third set of MRI and PET scans (MRI-3,
FET-3) was performed 6–8 weeks after the completion of
radiochemotherapy. Drawings of three-dimensional contrast-
enhancing volumes were used to delineate the tumors on the
MRI images, whereas a 1.6 cut-off tumor-to-background (TBR)
value was used to delineate tumor tissue in the [18F] FET
images based on previous findings on the best cut-off value
for distinguishing tumor tissue from non-tumor tissue (13).
The authors found that changes in the Gd-volumes observed
between MRI-1 and MRI-2 or MRI-3 scans did not have any
predictive value. However, a decrease of at least 20% of the
maximum tumor-to-background (TBRmax) value between the
FET-1 and FET-2 imaging enabled responders to be differentiated
from non-responders. The patients’ characteristics can be found
in Table 1.
CONSTRUCTING THE DECISION TREE
MODEL
A decision tree was developed using the Microsoft Office Word
program (Microsoft Office, version 1803) to compare the clinical
effectiveness of PET and MRI. This model was derived from
previously constructed decision trees reported in the literature
(14, 15). To develop the decision tree, the patients who featured in
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FIGURE 1 | Decision tree based on overall survival patients. 23 patients were available for PET analysis and 21 for MRI analysis. N1 & N2 gave chance node to be
responder (R) for, respectively, PET and MRI. Chance nodes N3 & N5 gave the chance to be a real responder (RR) with PET and MRI. N4 and N6 gave the chance to
be real non-responder (RNR) for PET and MRI. Non-responder (NR); non-real responder (NRR); and non-real non-responder (NRNR) are equal to 1 minus the chance
to be R; RR and RNR. N = number patients. P in most right transparent framework gives the total chance to this event (is calculated by multiplying the previous two
chance nodes).
the study by Galldiks et al. (12) were divided into two categories:
responders and non-responders according to differences found
in the characteristics of the images generated during the first
and subsequent PET and MRI scans (Figures 1, 2). Chance node
one (N1) indicated the possibility of a patient being a responder
according to [18F] FET PET features. The patient was defined as
a responder when there was a 20% decrease in the TBRmax value
obtained for FET-2 compared with the value obtained for FET-1.
Chance node two (N2) indicated the possibility of a patient being
a responder according to MR features defined as no change or a
decrease in the contrast-enhancing volume for MRI-2. In chance
node three (N3), the PET-responders were divided into true
responders and false responders on the basis of clinical endpoints.
Patients who were both clinical and PET responders were defined
as true responders. Those who were PET responders, but not
clinical responders were categorized as false responders. Patients
identified as non-responders on the basis of the PET images
were similarly assigned as true non-responders and false non-
responders in chance node four (N4). In chance node five
(N5), true responders were separated from false responders
according to their clinical endpoints and differential changes
in contrast-enhancing volumes. Chance node six (N6) showed
true non-responders and false non-responders, as identified from
MRI scans. A decision tree was developed for each of the two
clinical endpoints used. In the first decision tree, patients with
an overall survival rate of more than 10 months were considered
as clinical responders. This definition is arbitrarily based on the
median overall survival rate derived from Johnson et al. (16).
In the second decision tree, a clinical responder was defined
as one with a progression-free survival rate of 6 months or
more. A progression-free survival rate of 6 months has already
been shown to be the best indicator for differentiating between
long-term and short-term survivors (17, 18).
Because the prognosis after a glioblastoma diagnosis is
poor, it is of utmost importance to identify patients who are
not showing an early response to therapy. Accordingly, TMZ
maintenance therapy can be omitted, thereby avoiding possible
severe side effects, and a second line treatment can be proposed.
Hence, we calculated the probability of being able to identify
a non-responder.
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FIGURE 2 | Decision tree based on progression free survival patients. 23 patients were available for PET analysis and 21 for MRI analysis. N1 & N2 gave chance node
to be responder (R) for, respectively, PET and MRI. Chance nodes N3 & N5 gave the chance to be a real responder (RR) with PET and MRI. N4 and N6 gave the
chance to be real non-responder (RNR) for PET and MRI. Non-responder (NR); non-real responder (NRR); and non-real non-responder (NRNR) are equal to 1 minus
the chance to be R; RR and RNR. N = number patients. P in most right transparent framework gives the total chance to this event (is calculated by multiplying the
previous two chance nodes).
Cost Calculation
The costs associated with diagnosis using [18F] FET PET were
determined in the context of Belgian healthcare. The costs
included in the calculation were the reimbursement of expenses
incurred for services relating to the use of [18F] FET PET by the
National Institute for Health and Disability Insurance, which is
the federal public body responsible for social security provision in
Belgium. The cost-effectiveness of [18F] FET PET was expressed
as an incremental cost-effectiveness ratio (ICER).
There are two cost centers relating to [18F] FET PET imaging
at the Ghent University Hospital. The first entails government
incentives for the purchase and maintenance of PET scanners.
The second cost center entails reimbursement of expenses
incurred by the hospital through the provision of services relating
to the acquisition and interpretation of PET scans by the National
Institute for Health and Disability Insurance.
Cost-Effectiveness
The cost-effectiveness of [18F] FET PET used to assess
therapy responses to TMZ of patients with glioblastoma was
expressed as the ICER for each identified non-responder
as follows:
ICER =
Cost [18F]FET
Effectiveness [18F] FET − Effectiveness MRI
Sensitivity Analysis
To determine the impact of each independent variable on the
cost calculation, a one-way deterministic sensitivity analysis
was performed. We used confidence intervals derived from a
similar study (14), as shown in Table 2, to estimate the degree
of uncertainty regarding the parameters of the decision tree.
We also determined variability relating to the number of scans
performed annually, which influences the cost of [18F] FET
PET. The calculated results were plotted in a tornado diagram
(see Table 3).
A Monte Carlo simulation was performed to analyze the
probabilistic sensitivity. For each independent variable, 10,000
at random values within the normal distribution were chosen.
These values were used to calculate new ICER values. All of
the simulations were performed using the Microsoft Office Excel
program (Microsoft Office, version 1803).
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TABLE 1 | Patients’ characteristics: MRI and PET data for scans 1 and 2 conducted on each patient [Source: (12)].
MRI [Gd-volume (cm3)] PET (TBRmax) OS (months) PFS (months)
Nr. 1 2 Statusa 1 2 Statusb Months Statusc Months Statusd
1 0.9 4.3 0 2.6 / / 16.1 1 14.1 1
2 14.2 22.0 0 4.1 4.0 0 9.3 0 8.3 1
3 /e 14.8 / 3.5 4.6 0 5.6 0 5.1 0
4 6.0 3.7 1 3.6 2.8 1 22.8 1 9.4 1
5 31.6 5.2 1 4.1 3.4 0 6.9 0 5.4 0
6 0.6 2.7 0 3.6 3.0 0 28.5 1 7.2 1
7 6.1 0.5 1 4.6 3.2 1 28.5 1 19.3 1
8 0.0 0.0 1 2.0 1.7 0 14.8 1 13.9 1
9 1.3 6.4 0 2.3 3.2 0 9.3 0 4.7 0
10 1.1 0.6 1 3.7 2.3 1 16.1 1 5.3 0
11 16.8 8.7 1 3.3 3.3 0 2.8 0 2.8 0
12 1.6 0.9 1 2.2 1.5 1 28.7 1 28.7 1
13 5.2 / / 2.0 2.1 0 8.5 0 5.5 0
14 19.4 2.3 1 4.9 2.8 1 10.5 1 5.2 0
15 6.8 / / 3.6 2.5 1 14.8 1 10.3 1
16 19.5 3.9 1 4.8 3.8 1 14.3 1 3.3 0
17 8.2 0.4 1 3.3 2.6 1 15.4 1 12.9 1
18 0.8 6.2 0 3.1 2.5 0 9.8 0 7.8 1
19 1.3 6.9 0 3.8 2.4 1 20.9 1 9.3 1
20 2.2 0.6 1 3.1 2.5 0 8.2 0 6.6 1
21 4.9 4.6 1 2.9 2.6 0 9.9 0 5.8 0
22 3.7 2.8 1 2.4 2.8 0 13.8 1 3.8 0
23 0.1 1.8 0 2.4 2.0 0 15.7 1 15.7 1
24 6.5 / / 2.5 / / 6.8 0 5.2 0
25 6.4 0.0 1 2.0 1.4 1 13.3 1 13.3 1
aCriteria for MRI scan: R, Responder (Gd vol 2 < 1); NR, Non-responder (Gd vol 2 > 1). Status 1 = R; Status 2 = NR.
bCriteria for PET scan: R, Responder (TBRmax 2 < 80% TBRmax 1); NR, Non-responder (TBRmax 2 > 80% TBRmax 1). Status 1 = R; Status 2 = NR.
cCriteria for OS scan: R, Responder (OS > 10 months); NR, Non-responder (OS < 10 months). Status 1 = R; status 2 = NR.
dCriteria for PFS scan: R, Responder (PFS > 6 months); NR, Non-responder (PFS < 6 months). Status 1 = R; status 2 = NR.
e/, data not available.
TABLE 2 | Chance node intervals for decision tree 1 based on the overall survival
rate and for decision tree 2 based on the progression-free survival rate developed
for the one-way deterministic sensitivity analysis.
Chance
node
Interval decision
tree 1 (Chance=)
Interval decision
tree 2 (Chance=)
N1 0.2848 0.5848 0.2848 0.5848
N2 0.5167 0.8167 0.5167 0.8167
N3 0.9250 1.0000 0.6250 0.7750
N4 0.6173 0.7673 0.4635 0.6135
N5 0.6393 0.7893 0.4250 0.5750
N6 0.3536 0.5036 0.0679 0.2179
# scans 5,062 6,189 5,062 6,189
An interval of 30 percent points was chosen for chance nodes one and two while an
interval of 15 percent points was chosen for chance nodes three and four.
RESULTS
Effectiveness
Both decision trees showed that the use of [18F] FET PET
imaging increased the number of identified non-responders.
TABLE 3 | Input variables used in a Monte Carlo analysis.
Decision tree 1 Decision tree 2
Variable Calculated
value
Standard
deviation
Calculated
value
Standard
deviation
# scans 5,626 287 5,626 287
N1 0.4348 0.0750 0.4348 0.0750
N2 0.6667 0.0750 0.6667 0.0750
N3 1.0000 0.0375 0.7000 0.0375
N4 0.6923 0.0375 0.5385 0.0375
N5 0.7143 0.0375 0.5000 0.0375
N6 0.4286 0.0375 0.1429 0.0375
Calculated values and their standard deviations are shown for each variable applied in the
cost-effectiveness analysis.
The first decision tree constructed with the overall survival rate
showed that the number of non-responders identified using PET
imaging (100%) was 57.14% more than the number of non-
responders identified with MRI imaging (42.86%). The second
decision tree constructed with the progression-free survival
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TABLE 4 | Effect of the number of scans performed annually on the cost of [18F]
FET-based follow-up therapy.
Interval cost [18F] fluoroethyl-L-tyrosine scan
Lower limit interval Upper limit interval
Number of scans 5,063 6,189
Cost [18F]
fluoroethyl-L-tyrosine
813.20 euros 735.74 euros
TABLE 5 | Data used for decision tree 1 (overall survival rate) and decision tree 2
(progression-free survival rate) in the one-way deterministic sensitivity analysis.
Chance node Interval decision
tree 1 (chance =)
Interval decision
tree 2 (chance =)
N1 0.2848 0.5848 0.2848 0.5848
P event 0.5714 0.5714 0.6934 0.4353
N2 0.5167 0.8167 0.5167 0.8167
P event 0.4161 0.7481 0.4891 0.6397
N3 0.9250 1.0000 0.6250 0.7750
P event 0.4945 0.5714 0.5262 0.6318
N4 0.6173 0.7673 0.4635 0.6135
P event 0.5714 0.5714 0.5426 0.6017
N5 0.6393 0.7893 0.4250 0.5750
P event 0.6273 0.4958 0.5895 0.5561
N6 0.3536 0.5036 0.0679 0.2179
P event 0.6178 0.5316 0.6365 0.5211
A change in effectiveness was observed for every change in a chance node.
revealed a comparable increase (57.5%) in the identification of
non-responders with PET (70%) compared to MRI (12.5%).
Cost Calculation
The total cost calculated for the follow-up phase for each patient
was 780.50 euros (see Supplementary Material). The resulting
ICER values calculated for the first and second decision tree were
1,365.86 and 1,357.38 euros, respectively for each non-responder
identified on PET but not on MRI.
Sensitivity Analysis
Tables 4, 5 present the results of the one-way sensitivity analysis,
and Figure 3 depicts the tornado diagrams. The minimum
and maximum ICER values were 1,043.28 and 1,875.68 euros,
respectively, for the first decision tree and 1,125.54 and 1,792.88
euros, respectively, for the second decision tree. The minimum
and maximum costs of a follow-up [18F] FET PET session were
613.74 and 813.20 euros, respectively. N1 and N2 showed the
greatest impacts relating the minimum and maximum ICER
values, which were direct outcomes of the wider variability.
The results of the Monte Carlo analysis, depicted in Figure 4,
showed a narrow distribution of the ICER values around the
average. This finding implies high levels of data robustness and
of the reliability of the calculated values (see Tables 6, 7).
TABLE 6 | Data obtained from the Monte Carlo analysis conducted for decision
tree 1.
Cost FET (e) P Corr NR ICER (e)
Average 781.2 0.5582 1,444
Maximum 851.2 0.9207 3,531
Minimum 726.8 0.2242 837
Standard deviation 15.2 0.0957 273.5
Average, maximum values, minimum values, and their standard deviations, were obtained
for the following parameters: cost of [18F] fluoroethyl-L-tyrosine study (cost FET),
possibility of identifying non-responders (P corr NR, chance correct non-responder), and
the incremental cost-effectiveness ratio (ICER).
TABLE 7 | Data obtained from the Monte Carlo analysis conducted for decision
tree 2.
Cost FET (e) P Corr NR ICER (e)
Average 781.1 0.5704 1,405
Maximum 846.2 0.8208 3,083
Minimum 733.4 0.2458 948
Standard deviation 15.3 0.0862 241.8
The average, maximum, and minimum values, and their standard deviations, were
obtained for the following parameters: cost of [18F] fluoroethyl-L-tyrosine study (cost FET),
possibility of recognizing non-responders (P corr NR, chance correct non-responder), and
the incremental cost-effectiveness ratio (ICER).
DISCUSSION
Given limited resources available for health care, it is essential
to ensure optimally efficient allocation of financial resources.
With the development of new diagnostic imaging modalities,
clinicians can tailor the therapy for individual patients. However,
most imaging techniques require substantial investments and
should ideally be used only when there are indications that
the added value outweighs the cost. In this context, the cost-
effectiveness of [18F] FET PET for assessing the therapy response
of patients with glioblastoma to TMZ treatment was investigated.
Our data indicated that the identification of non-responders at a
low incremental cost was feasible. In addition, the results of the
sensitivity analysis revealed that these calculations were robust,
implying that there was a low level of variability.
The use of PET as a prognostic tool for high-grade gliomas has
been investigated over a period of several years. A previous study
conducted on [18F] dihdryoxyphenylalanine ([18F] FDOPA)
within a large target population did not find that the amino
acid PET tracer had any prognostic power (19). However,
studies on [18F] FET have shown that this tracer could have
prognostic potential (12, 13). These conflicting results can be
attributed to differences in target populations or in PET tracers.
The results of our decision tree model indicate that [18F] FET
can enable the differentiation of long-term survival and short-
term survival. Three studies conducted by Heinzel et al. have
confirmed the cost-effectiveness of the [18F] FET PET modality
for patients with glioblastoma (14, 15, 20). In the first study,
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FIGURE 3 | Tornado diagram of the cost-effectiveness ratio for decision tree one (left), based on overall survival (OS) and two (right), based on progression free
survival (PFS).
FIGURE 4 | Monte Carlo simulation of the incremental cost-effectiveness ratio for decision tree one (left), based on overall survival and two (right), based on
progression free survival. The chart shows the relative frequency of the probability on a certain incremental cost-effectiveness.
the authors calculated the cost-effectiveness of [18F] FET PET-
guided biopsy for diagnosing gliomas (20). The second study
investigated the cost-effectiveness of managing [18F] FET PET-
based therapy using bevacizumab and irinotecan (14). The third
study examined the cost-effectiveness of [18F] FET PET in
the evaluation of recurrent metastasis in the brain (15). The
ICER values reported in the three papers varied between 2,821
and 9,114 euros per diagnosis, depending on indications and
scenarios. In our study, we investigated the cost-effectiveness
of [18F] FET PET used in TMZ therapy management. Our
results showed an ICER value for each identified non-responder.
However, comparison of our results to the literature was difficult
because ICER values were expressed per non-responder instead
of per diagnosis. Therefore, we provided additional ICER values
of 3,769.77 euros and 2,427.07 euros per diagnosis obtained,
respectively, for overall survival and progression-free survival
rates in the section with Supplemental Information. These
values are in line with the ICER values reported in the above-
mentioned studies by Heinzel et al.
In light of our results, we recommend the use of [18F] FET
PET scans during the follow-up treatment phase for patients
with glioblastoma. The use of this diagnostic modality enables
the identification of non-responders at an early stage and at
an acceptable cost. Moreover, the avoidance of ineffective TMZ
maintenance therapy in non-responders is cost-effective and
results in considerable cost-saving.
The data described here merely represent a starting point for
further research. It should also be noted that there were several
shortcomings in our study. Only 25 patients were included in
the study conducted by Galldiks et al. (12) that constituted the
basis for our construction of the decision trees in this study.
This limited sample of patients led to increased variability in the
clinical data.
The differentiation of clinical responders and non-responders
in this study was based on both the overall survival and
progression-free survival rates. In the first decision tree, the
criterion used to define a clinical responder was an overall
survival rate of a minimum of 10 months. This criterion
was derived from the median overall survival rate of patients
diagnosed with glioblastoma, which was 10 months (16).
However, it is important to note that the median overall
survival rate identifies the overall survival of 50% of the patient
population and does not provide any information relating to
long-term and short-term survival. Consequently, a second
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decision tree was developed, using the criterion of a progression-
free survival rate of 6 months to divide the patients into
clinical responders and non-responders. Although a progression-
free survival rate of 6 months has already been shown to
be valid for distinguishing long-term survivors from short-
term survivors, it is not a primary endpoint in clinical trials.
Because both overall survival and progression-free survival rates
each have their merits, two decision trees were constructed.
Notably, ICER values obtained for both decision trees were
very similar.
Galldiks et al. (12) conducted a comparative study of PET and
MRI. It is important to note that in clinical practice, a PET scan
will generally be performed alongside an MRI scan for patients
with glioblastoma. Therefore, the cost of the MRI scan was not
subtracted from that of the [18F] FET PET scan in the ICER
calculations. Consequently, a comparison of the cost of MRI with
the combined cost of PET and MRI would also be appropriate.
It is possible that combining both image modalities could lead
synergistically to greater accuracy in terms of specificity and/or
sensitivity than through their individual use. Advanced MR
sequences also provide metabolic information to some extent.
Therefore, it would be of great interest to do a comparing cost-
effectiveness study between advanced MR sequences and PET to
see which modality is the most cost-effective.
Therapy-related effects on imaging cannot be excluded. The
findings of Chiaravalloti et al. suggest that radiotherapy has a
long-term influence on the results of PET scans (21). However,
an effective intervention entailing a follow-up PET scan in
maintenance therapy necessitates its performance shortly after
radiochemotherapy has been completed.
CONCLUSION
[18F] FET PET is a valuable tool that enables the treatment
outcome to be predicted prior to commencing maintenance
TMZ therapy in patients with glioblastoma. It is, therefore, more
cost-effective than conventional MRI. Specifically, it enables the
clinical outcome to be predicated accurately and at a low cost. In
addition, the results of our sensitivity analyses indicated that this
outcome could be achieved with an acceptable level of certainty
given the robustness of the data.
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